Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Description

Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk of premature ovarian failure from radiotherapy. Premature ovarian failure carries significant cardiac, musculoskeletal, sexual, and psychosocial morbidity. Ovarian transposition carries variable success rates, is not readily accessible to the general population, and can still be at risk of clinically significant radiotherapy doses. There is an unmet need for innovative techniques to protect ovarian function.

Conditions

Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer

Study Overview

Study Details

Study overview

Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk of premature ovarian failure from radiotherapy. Premature ovarian failure carries significant cardiac, musculoskeletal, sexual, and psychosocial morbidity. Ovarian transposition carries variable success rates, is not readily accessible to the general population, and can still be at risk of clinically significant radiotherapy doses. There is an unmet need for innovative techniques to protect ovarian function.

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women (OvAR-Y): an In-Silico Feasibility Trial

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Condition
Uterine Cancer
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Biologic female
  • * Age between 18 and 50 years old (inclusive)
  • * Clinically premenopausal (defined as having active, regular menstruation without vasomotor symptoms)
  • * At least one of two ovaries readily visualized on diagnostic CT or MR imaging as confirmed by radiologist
  • * Planning to receive radiation therapy (for any indication)
  • * Ability to understand and willingness to sign an IRB-approved written informed consent document.
  • * Prior pelvic radiation
  • * Prior cancer therapies that are known to impact ovarian function
  • * Prior diagnosis of ovarian insufficiency/failure or menopause
  • * Clinically peri- or post-menopausal
  • * For patients \> 45 years old, if there is a clinical history of vasomotor symptoms OR irregular periods, then the patient must be excluded.
  • * For patients ≤ 45 years old, if there is a history of vasomotor symptoms consistent with menopause OR irregular menstruation for ≥3 months OR recent changes in their menstrual cycle \> 14 days, then the patient must be excluded.
  • * Surgically removed or transposed ovaries
  • * Pregnant and/or breastfeeding

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Washington University School of Medicine,

Hyun Kim, M.D., PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

2026-04-15